CSIMarket
 
Icad Inc  (ICAD)
Other Ticker:  
 
 
Price: $1.5900 $-0.02 -1.242%
Day's High: $1.715 Week Perf: -9.4 %
Day's Low: $ 1.57 30 Day Perf: 9.66 %
Volume (M): 249 52 Wk High: $ 3.97
Volume (M$): $ 395 52 Wk Avg: $1.71
Open: $1.60 52 Wk Low: $1.05



 Market Capitalization (Millions $) 41
 Shares Outstanding (Millions) 26
 Employees -
 Revenues (TTM) (Millions $) 22
 Net Income (TTM) (Millions $) -10
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 1

Icad Inc
ICAD Inc. is a medical technology company headquartered in Nashua, New Hampshire. The company specializes in developing advanced cancer detection and radiation therapy treatment solutions. It primarily focuses on products and services related to improving cancer detection accuracy and treatment outcomes.

One of the major innovations offered by ICAD Inc. is its advanced imaging technology called PowerLook' TomoDetection'. This technology assists radiologists in identifying potential abnormal tissues in breast images with greater accuracy and efficiency, aiding in early detection of breast cancer.

ICAD Inc. is also known for its Xoft' Axxent' Electronic Brachytherapy (eBx') System', which offers a non-invasive and targeted radiation therapy solution for various types of cancer treatments, including breast, skin, and gynecological cancers. The system is designed to provide precise and localized radiation treatment, reducing potential side effects and improving patient comfort.

Overall, ICAD Inc. is dedicated to advancing the field of cancer detection and radiation therapy by providing cutting-edge technology solutions that enhance patient care and improve overall treatment outcomes.


   Company Address: 98 Spit Brook Road, Suite 100 Nashua 3062 NH
   Company Phone Number: 882-5200   Stock Exchange / Ticker: NASDAQ ICAD
   ICAD is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Changes

iCAD Expands Sales Leadership Team and Adds Key Executives to Accelerate Growth Amidst New Products and Partnerships

Published Mon, Dec 18 2023 1:00 PM UTC



As iCAD Inc, a leading healthcare technology company, continues to expand its business and enhance its product offerings, it has made important additions to its executive sales leadership team. Bill Keyes, an existing member of the team, has transitioned to the role of Senior Vice President, Global Sales Operations. Additionally, Peter Graham has joined iCAD as the...

Icad Inc

Icad Inc: Reigniting Revenue Growth in the Third Quarter of 2023


By
As an investor closely following the latest financial developments, I am always on the lookout for companies that exhibit resilience and strategic growth potential. One such company that has captured my attention is Icad Inc. Despite the challenges posed by the economic climate, their recent financial results for the third quarter of 2023 have showcased some positive trends.
First and foremost, let us address the bottom line. Icad has managed to significantly reduce its loss per share, recording a decrease from $-0.15 per share a year prior to $-0.05 per share. Moreover, their third-quarter EPS improved from $-0.07 per share in the previous quarter. This emphasizes the company's commitment to efficiency and profitability, even during a tough market environment.

Icad Inc

Icad Inc's Financial Report Reveals Significant Improvement in Profitability and Income per Share for the Period Ending June 30, 2023

Icad Inc: A Financial Overview
Icad Inc, a company specializing in a particular industry, has recently released its financial report for the period ending June 30, 2023. This report provides valuable insights into the company's performance and highlights key financial indicators that investors and analysts can use to evaluate the company's stability and growth potential.
One of the key highlights of the report is the decrease in the company's loss per share. Over the past year, Icad Inc has managed to reduce its loss per share from $-0.12 to $-0.07, indicating an improvement in its profitability. Additionally, the company has seen an improvement in its income per share, rising from $-0.15 per share in the previous financial reporting period.

Icad Inc

ICAD's First Quarter of 2023 Earnings Season Indicates Worsening Diminishing Returns

ICAD Inc., a leader in cancer detection and treatment, recently reported a rise in losses for its most recent fiscal period. The root cause of this loss was attributed to weak business performance, which led to a shortfall per share rising from $-0.14 to $-0.15.
One of the key indicators of this poor performance was a decrease in revenue. In comparison to the previous year, ICADs Q4 revenue deteriorated by -10.971% from $6.49 million. Additionally, revenue fell by -23.196% for the latest fiscal period, to $5.78 million from $7.52 million. This substantial reduction can be attributed to a range of factors such as increased competition or changes in consumer behaviours.






 

Icad Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com